Vivozon Pharmaceutical Statistics

Total Valuation

Vivozon Pharmaceutical has a market cap or net worth of KRW 449.85 billion. The enterprise value is 477.76 billion.

Market Cap	449.85B
Enterprise Value	477.76B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Vivozon Pharmaceutical has 49.38 million shares outstanding. The number of shares has decreased by -0.49% in one year.

Current Share Class	n/a
Shares Outstanding	49.38M
Shares Change (YoY)	-0.49%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	n/a
Float	16.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.95
PB Ratio	4.12
P/TBV Ratio	4.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 61.07, with an EV/FCF ratio of -809.89.

EV / Earnings	-176.11
EV / Sales	5.47
EV / EBITDA	61.07
EV / EBIT	111.53
EV / FCF	-809.89

Financial Position

The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.38.

Current Ratio	0.64
Quick Ratio	0.18
Debt / Equity	0.38
Debt / EBITDA	5.08
Debt / FCF	-67.39
Interest Coverage	1.99

Financial Efficiency

Return on equity (ROE) is -2.75% and return on invested capital (ROIC) is 1.81%.

Return on Equity (ROE)	-2.75%
Return on Assets (ROA)	1.51%
Return on Capital (ROIC)	1.81%
Revenue Per Employee	266.08M
Profits Per Employee	-8.27M
Employee Count	328
Asset Turnover	0.49
Inventory Turnover	2.66

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +197.23% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+197.23%
50-Day Moving Average	6,578.50
200-Day Moving Average	4,158.15
Relative Strength Index (RSI)	58.39
Average Volume (20 Days)	2,722,358

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vivozon Pharmaceutical had revenue of KRW 87.28 billion and -2.71 billion in losses. Loss per share was -57.36.

Revenue	87.28B
Gross Profit	43.81B
Operating Income	4.28B
Pretax Income	-2.88B
Net Income	-2.71B
EBITDA	7.82B
EBIT	4.28B
Loss Per Share	-57.36

Full Income Statement

Balance Sheet

The company has 11.85 billion in cash and 39.76 billion in debt, giving a net cash position of -27.91 billion or -565.24 per share.

Cash & Cash Equivalents	11.85B
Total Debt	39.76B
Net Cash	-27.91B
Net Cash Per Share	-565.24
Equity (Book Value)	105.10B
Book Value Per Share	2,211.85
Working Capital	-23.43B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.21 billion and capital expenditures -7.80 billion, giving a free cash flow of -589.90 million.

Operating Cash Flow	7.21B
Capital Expenditures	-7.80B
Free Cash Flow	-589.90M
FCF Per Share	-11.95

Full Cash Flow Statement

Margins

Gross margin is 50.19%, with operating and profit margins of 4.91% and -3.11%.

Gross Margin	50.19%
Operating Margin	4.91%
Pretax Margin	-3.31%
Profit Margin	-3.11%
EBITDA Margin	8.96%
EBIT Margin	4.91%
FCF Margin	n/a

Dividends & Yields

Vivozon Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.49%
Shareholder Yield	0.49%
Earnings Yield	-0.63%
FCF Yield	-0.13%

Stock Splits

The last stock split was on October 20, 2023. It was a reverse split with a ratio of 0.2.

Last Split Date	Oct 20, 2023
Split Type	Reverse
Split Ratio	0.2

Scores

Vivozon Pharmaceutical has an Altman Z-Score of -0.35. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.35
Piotroski F-Score	n/a